Stock Spotlight Archives - Page 157 of 397

FridayDec 03, 2021 12:18 pm

QualityStocksNewsBreaks – Sugarmade Inc. (SGMD) Expanding End-Market Access in Growing California Cannabis Delivery Sector

Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis sector, is focused on expanding its end-market access as a central player in the growing space. This comes as more consumers around the world become aware of the potential benefits of cannabis. As a result, the market is projected to see significant growth, with a new Quince Market Insights report estimating that the global cannabis market will grow at a CAGR of 27.0% from 2021 to 2030 (https://ibn.fm/3WgpH) (https://nnw.fm/ESCca) (https://cnw.fm/pZlDm). “The growth factors identified in the market are the proven medicinal effects and legalization of cannabis, developments in intellectual property…

ThursdayDec 02, 2021 1:27 pm

QualityStocksNewsBreaks – Excellon Resources Inc.’s (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) Platosa Marks 4th Quarter of >21,000 Tons Mined and Milled

Excellon Resources (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) is a diversified metals producer with a precious metals growth pipeline that includes Mexico’s Platosa Mine, Kilgore, a high-quality gold development project in Idaho, as well as and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany boasting more than 750 years of mining history. The company recently released details of its robust second-quarter production numbers generated from its Durango, Mexico-based Platosa Mine. “Excellon saw silver production of 296,013 ounces, lead production of 1.9 million pounds and zinc production of 2.5 million pounds — in aggregate totaling…

ThursdayDec 02, 2021 12:38 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

ThursdayDec 02, 2021 11:42 am

QualityStocksNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space

Simply Sonoma, a company committed to offering CBD products for the environmentally conscious consumer, is branching out into the beverage space with an alcohol-free, CBD wine product as well as a Pinot Noir/CBD sparkling product. A Facts and Factors report expects that the global CBD-infused beverages market will grow at a CAGR of approximately 27.5% between 2021 and 2026, driven by the rising authorization and certification for recreational cannabis in countries such as the United States and Canada (https://ibn.fm/rQu00). Furthermore, there is a growing movement away from smoking cannabis and adopting healthier edible options because of the increasing incidence of…

WednesdayDec 01, 2021 2:51 pm

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one of its lead drug candidates. Nanoemulsion is an advanced drug delivery system that offers enhanced stability, fast digestibility, controlled release and protection against degradation. “Specifically, Mydecine is targeting the enhanced bioavailability and controlled capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will…

WednesdayDec 01, 2021 2:43 pm

QualityStocksNewsBreaks – Friendable Inc. (FDBL) Providing Artists, Fans the Best that Music Offers

Friendable (OTC: FDBL), a mobile technology and marketing company, released Fan Pass in July 2020 as a platform for artists to share their work and fans to get a front-row seat to the action from the comfort of their home. Since then, the platform has grown considerably. “During the latter part of 2021, the company’s main focus has been to make the Fan Pass platform more visible and accessible. Now, the company is focusing on moving into 2022, offering artists and fans the best that music offers,” reads a recent article. “Artists who sign up with the Fan Pass platform…

WednesdayDec 01, 2021 2:40 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of comorbidities that include anxiety, depression, poor sleep quality and other conditions. Tryp expects to initiate the study in 2022, subject to a favorable…

TuesdayNov 30, 2021 3:11 pm

QualityStocksNewsBreaks – Tingo Inc. (IWBB) Ranking Amongst Rarest of Companies

Tingo (OTCQB: IWBB) recently applied to list its shares for trading with the New York Stock Exchange (“NYSE”), forming part of efforts to broaden its appeal to U.S. and international investors. Although there are no guarantees that its listing application will be accepted, the company has reiterated its belief that it will satisfy the NYSE’s initial listing criteria. A recent article quotes Tingo CEO Dozy Mmobuosi as saying: “The NYSE is the main stock exchange in the United States and one that will raise our profile to the broader investment community. The bottom-up list will increase liquidity in our stocks…

TuesdayNov 30, 2021 12:10 pm

QualityStocksNewsBreaks– Nemaura Medical Inc. (NASDAQ: NMRD) CEO to Present at Benzinga Global Small Cap Conference

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference. The event is scheduled to be held virtually from Dec. 8-9, 2021. Dr. Chowdhury will deliver his corporate presentation at 3:00 p.m. ET on Dec. 8 and will be available for one-on-one meetings throughout the conference. Interested parties should visit https://ibn.fm/puHmj to register for the event. To view the full press release, visit https://ibn.fm/RJcQX About Nemaura Medical Inc. Nemaura Medical…

TuesdayNov 30, 2021 11:37 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs

InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio) that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s, Parkinson’s, Huntington’s and others – by providing protection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. According to InMed’s Senior VP Pre-Clinical Research & Development Dr. Eric Hsu, who is quoted in a recent article, “This PCT patent application advances our strategy directed towards researching and…

Site Search

Company Search

Category: Stock Spotlight